We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.71B
AUM Growth
-$70.8M
Cap. Flow
-$26.8M
Cap. Flow %
-1.56%
Top 10 Hldgs %
65.15%
Holding
70
New
6
Increased
13
Reduced
5
Closed
21

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$30.3M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$24.8M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$23.4M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$22.7M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$21.8M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$41.4M
2
DSGN icon
Design Therapeutics
DSGN
+$32.4M
3
ETNB
89bio
ETNB
+$25.6M
4
AXSM icon
Axsome Therapeutics
AXSM
+$24.4M
5
VRDN icon
Viridian Therapeutics
VRDN
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.77%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
51
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-39,000
Closed -$3.55M
ARQT icon
52
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-800,000
Closed -$7.62M
ATXS
53
DELISTED
Astria Therapeutics
ATXS
– –
-1,000,000
Closed -$8.33M
AVIR icon
54
Atea Pharmaceuticals
AVIR
$420M
– –
-1,547,181
Closed -$5.79M
AXSM icon
55
Axsome Therapeutics
AXSM
$10.9B
– –
-340,000
Closed -$24.4M
BBIO icon
56
PUT
BridgeBio Pharma
BBIO
$16.5B
– –
-810,800
Closed -$13.9M
DSGN icon
57
Design Therapeutics
DSGN
$876M
– –
-5,150,000
Closed -$32.4M
ETNB
58
DELISTED
89bio
ETNB
– –
-1,350,000
Closed -$25.6M
DMRA
59
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
– –
-40,810
Closed -$2.57M
CYPH
60
Cypherpunk Technologies Inc
CYPH
$73.3M
– –
-1,073,046
Closed -$3.36M
OCUL icon
61
Ocular Therapeutix
OCUL
$2.02B
– –
-645,000
Closed -$3.33M
PTGX icon
62
Protagonist Therapeutics
PTGX
$9.44B
– –
-1,500,000
Closed -$41.4M
SRPT icon
63
Sarepta Therapeutics
SRPT
$1.77B
– –
-130,000
Closed -$14.9M
VRDN icon
64
Viridian Therapeutics
VRDN
$2.67B
– –
-850,000
Closed -$20.2M
LENZ
65
LENZ Therapeutics
LENZ
$168M
– –
-28,507
Closed -$519K
MORF
66
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-150,000
Closed -$8.6M
BCEL
67
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-319,057
Closed -$313K
LIAN
68
DELISTED
LianBio American Depositary Shares
LIAN
– –
-4,250,000
Closed -$9.69M
GRNA
69
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
– –
-9,188,659
Closed -$2.74M
ISEE
70
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-300,000
Closed -$11.8M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Cormorant Asset Management held 70 positions worth $1.71B, down 4% from $1.79B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Cormorant Asset Management's Q3 2023 filing shows 6 new, 13 increased, 5 reduced and 21 closed positions. Its largest new stake was RayzeBio, Inc. Common Stock: 1,182,263 shares worth $26.2M. The largest sale was Protagonist Therapeutics, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Cormorant Asset Management's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,182,263 shares worth $26.2M.
  • Cormorant Asset Management added most to Apellis Pharmaceuticals in Q3 2023, an estimated $30.3M increase.
  • Cormorant Asset Management's biggest Q3 2023 reduction was Enliven Therapeutics, cutting an estimated $12.1M.
  • Cormorant Asset Management fully exited Protagonist Therapeutics in Q3 2023, selling an estimated $41.4M.
  • Cormorant Asset Management's ten largest holdings make up 65% of its $1.71B portfolio in Q3 2023.
  • Cormorant Asset Management opened 6 new positions and closed 21 in Q3 2023.
  • Cormorant Asset Management's portfolio value fell 4% quarter-over-quarter to $1.71B.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.